CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer
1998

CD44 Isoform Expression and Prognosis in Early-Stage Vulvar Cancer

Sample size: 70 publication Evidence: moderate

Author Information

Author(s): C Tempfer, G Sliutz, G Haeusler, P Speiser, A Reinthaller, G Breiteneckerl, N Vavra, Ch Kainz

Primary Institution: University of Vienna Medical School

Hypothesis

Is CD44 isoform expression a prognostic factor in early-stage squamous cell cancer of the vulva?

Conclusion

CD44 isoform expression, particularly CD44v3 and CD44v6, is correlated with poorer relapse-free and overall survival in early-stage vulvar cancer patients.

Supporting Evidence

  • Patients with tumors expressing CD44v6 had poorer relapse-free and overall survival.
  • Patients with tumors expressing CD44v3 also had poorer relapse-free and overall survival.
  • CD44v5 and CD44v7-8 did not show significant prognostic value.

Takeaway

This study found that certain proteins in vulvar cancer can help doctors predict how well patients will do after treatment.

Methodology

Immunohistochemical analysis of CD44 isoform expression in tumor samples from 70 patients with early-stage vulvar cancer.

Limitations

No groin dissection was performed, which may have missed micrometastases.

Participant Demographics

Mean age of participants was 62 years, with a range from 39 to 77 years.

Statistical Information

P-Value

0.02 for CD44v6, 0.04 for CD44v3, 0.03 overall survival for CD44v6, 0.01 overall survival for CD44v3

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication